Everolimus [159351-69-6]
Referentie HY-10218-10mg
Formaat : 10mg
Merk : MedChemExpress
Evérolimus (RAD001) est un dérivé de la rapamycine et un inhibiteur de mTOR1 puissant, sélectif et oralement actif. Evérolimus se lie à FKBP-12 pour générer un complexe immunosuppresseur. Evérolimus inhibe la prolifération des cellules tumorales et induit l'apoptose et l'autophagie des cellules. Evérolimus a des activités puissantes immunosuppressives et anticancéreuses.
Everolimus (RAD001) ist ein Rapamycin-Derivat und ein potenter, selektiver und oral aktiver mTOR1-Inhibitor. Everolimus bindet an FKBP-12 und bildet einen immunsuppressiven Komplex. Everolimus hemmt die Proliferation von Tumorzellen und induziert apoptosis und autophagy. Everolimus hat starke immunsuppressive und krebsbekämpfende Aktivitäten.
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
Everolimus Chemical Structure
CAS No. : 159351-69-6
This product is a controlled substance and not for sale in your territory.
Based on 96 publication(s) in Google Scholar
Other Forms of Everolimus:
- Everolimus-d4 In-stock
-
Everolimus purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 Jun;10(6):1004-1019. [Abstract]
- ECa109 cells stably transfected with control shRNA or RICTOR shRNA were treated with RAD001 (10 μmol/L) or PP242 (2 μmol/L) for 48 h, and total proteins were extracted to analysis the expression of RICTOR, p-AKT (Ser473), AKT, p-PRAS40 (Thr246), PRAS40, p-p70S6K and p70S6K by Western blot (n=5).
-
Everolimus purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2020 Jun;10(6):1004-1019. [Abstract]
- Total proteins in tumor tissues from nude mice were extracted and the expressions of RICTOR, p-AKT (Ser473), AKT, p-PRAS40 (Thr246), PRAS40, p-p70S6K (Thr389) and p70S6K were evaluated by Western blot (n=5). Values represent the mean±SD.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Mol Cancer Res. 2019 Jan;17(1):42-53. [Abstract]
- Combination of Everolimus with AZD2281 (left panel) and AZD2014 with AZD2281 (right panel) activates the RIPK1 Ser 166 phosphorylation in Clone A and SF-539 cells respectively.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Prostate. 2019 Jan;79(1):44-53. [Abstract]
- Treatment with sub-dose of Everolimus (10 nM), together with CQ (5 µM) increases the levels of Bax and cleaved PARP, and decreases the levels of Bcl-2 expression in both PC3 and LNPER cells.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Nutrients. 2018 Dec 8;10(12). pii: E1950. [Abstract]
- Western analysis of protein expression in cells treatmented with or without PLX4032 or RAD001.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]
- HUT-102 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]
- ATL-43T cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]
- ED-40415 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2018 Jan;109(1):103-111. [Abstract]
- MT-2 cell lines are treated for 0 and 60 min with control (DMSO), Rapamycin, everolimus, LY294002, PP242 and AZD8055. After treatment, protein lysates are immunoblotted for expression of phosphorylated mTOR S2448 (mTORC1), S2481 (mTORC2), total mTOR, p-Akt S473, total Akt, p-p70S6k, total p70S6k, and actin.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2018 Apr 19;12:911-920. [Abstract]
- 786-O and A498 cell lines are treated by RAD001 with different concentrations for 24 hours. Immunoblotting shows that RAD001 induces autophagy indicators including upregulation of LC3-II/I and downregulation of p62 in a dose-dependent manner.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2018 Apr 19;12:911-920. [Abstract]
- Immunoblotting demonstrates that AZD6244 can effectively restore upregulation of LC3-II/I and downregulation of p62 induced by RAD001 in 786-O and A498 cells.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2017 Nov 1;408:43-54. [Abstract]
- Western blot analysis of p-p70S6k, p70S6k, p-AKT and AKT after 6 h of treatment with 20 μM Everolimus. Levels of p-p70S6k and p-AKT are quantified by densitometric analysis and a corresponding histogram is constructed as relative to p70S6k or AKT and α-tubulin. The lower panel shows a representative Western blot.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Molecules. 2017 Dec 12;22(12). pii: E2207. [Abstract]
- p-AKT level in NRK cells treated with 5 nM RAD-001, 1 μM Resveratrol and their combination for 2 h and analyzed by Western blotting. Blots from 3 independent experiments are used for quantification.
-
Everolimus purchased from MedChemExpress. Usage Cited in: PLoS One. 2016 Jan 28;11(1):e0147682. [Abstract]
- CHP-212 and SK-N-AS cells are treated with indicated concentrations of AZD6244, MEK162, Everolimus or AZD8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot. Phosphorylation levels of AKT, ERK and S6 are detected by specific anti-phospho antibodies. Loading is verified by specific antibodies to total AKT, ERK and anti-tubulin.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Oncotarget. 2015 Dec 8;6(39):42183-96. [Abstract]
- KNS-62 and T24 cells are treated with 250 nM AZD6244, 250 nM MEK162, 5 nM of Everolimus, 250 nM AKT8055 or combinations thereof as indicated for 1 hour. Then, cells are lysed and analysed by Western blot.
-
Everolimus purchased from MedChemExpress. Usage Cited in: Sci Transl Med. 2013 Jul 31;5(196):196ra99. [Abstract]
- Apoptosis and PI3K/Akt/mTOR pathway inhibition in cells treated with BYL719, RAD001, or the combination. Protein lysates from HCC1954 and JIMT-1 cells treated for 18 hours with 0.5 μM BYL719, 1 nM RAD001 or the combination are analyzed by immunoblotting against the indicated proteins. Data are shown as mean ± SEM. p-value is calculated using two-sided student’s t-test.